


## H-Ile-Lys-Val-Ala-Val-OH

<b>Cat. No.:</b>	HY-P4322
<b>CAS No.:</b>	131167-89-0
<b>Molecular Formula:</b>	C <sub>25</sub> H <sub>48</sub> N <sub>6</sub> O <sub>6</sub>
<b>Molecular Weight:</b>	528.69
<b>Sequence:</b>	H-Ile-Lys-Val-Ala-Val-OH
<b>Sequence Shortening:</b>	IKVAV
<b>Target:</b>	ERK; Akt
<b>Pathway:</b>	MAPK/ERK Pathway; Stem Cell/Wnt; PI3K/Akt/mTOR
<b>Storage:</b>	Sealed storage, away from moisture Powder -80°C 2 years -20°C 1 year

\* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

#### In Vitro

H<sub>2</sub>O : 100 mg/mL (189.15 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent		1 mg	5 mg	10 mg
	Concentration	Mass			
	1 mM		1.8915 mL	9.4573 mL	18.9147 mL
	5 mM		0.3783 mL	1.8915 mL	3.7829 mL
	10 mM		0.1891 mL	0.9457 mL	1.8915 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

H-Ile-Lys-Val-Ala-Val-OH is one of the most potent active sites of laminin-1. H-Ile-Lys-Val-Ala-Val-OH promotes cell adhesion, neurite outgrowth, and tumor growth. H-Ile-Lys-Val-Ala-Val-OH stimulates BMMSC population growth and proliferation by activating MAPK/ERK1/2 and PI3K/Akt signalling pathways<sup>[1][2]</sup>.

#### IC<sub>50</sub> & Target

ERK1	ERK2	Akt
------	------	-----

#### In Vitro

H-Ile-Lys-Val-Ala-Val-OH (0-2.5 mM, 0-48 h) induces proliferation and proliferating cell nuclear antigen (PCNA) synthesis of bone marrow mesenchymal stem cell (BMMSC)<sup>[2]</sup>.

H-Ile-Lys-Val-Ala-Val-OH (5 mM, 24 h) induces the BMMSC cell cycle for cells to enter S phase from G<sub>0</sub>/G<sub>1</sub> and arrests them from entering G<sub>2</sub>/M phase<sup>[2]</sup>.

H-Ile-Lys-Val-Ala-Val-OH (0-2.5 mM, 0-48 h) activates MAPK/ERK and PI3K/Akt signalling pathways by enhancing phosphorylation levels of ERK1/2 and Akt in the BMMSCs<sup>[2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

#### Cell Proliferation Assay<sup>[2]</sup>

Cell Line:	BMMSC
Concentration:	0, 0.004, 0.02, 0.1, 0.5 and 2.5 mM
Incubation Time:	0, 12, 24, 36, 48 h
Result:	Stimulated proliferating cell nuclear antigen (PCNA) synthesis and induced proliferation of bone marrow mesenchymal stem cell (BMMSC) in a dose- and time-dependent manner.

#### Cell Cycle Analysis<sup>[2]</sup>

Cell Line:	BMMSC
Concentration:	5 mM
Incubation Time:	24 h
Result:	Induced the BMMSC cell cycle for cells to enter S phase from G0/G1 and arrested them from entering G2/M phase; the increased proportion of S phase in cell cycle was considered to be a sign of BMMSC proliferation.

#### Western Blot Analysis<sup>[2]</sup>

Cell Line:	BMMSC
Concentration:	0, 0.004, 0.02, 0.1, 0.5 and 2.5 mM
Incubation Time:	0, 12, 24, 36, 48 h
Result:	Increased significantly the levels of p-ERK1/2 and p-Akt in a dose- and time-dependent manner.

---

## REFERENCES

[1]. Nomizu M, et al. The all-D-configuration segment containing the IKVAV sequence of laminin A chain has similar activities to the all-L-peptide in vitro and in vivo. *J Biol Chem.* 1992 Jul 15;267(20):14118-21.

[2]. Li B, et al. IKVAV regulates ERK1/2 and Akt signalling pathways in BMMSC population growth and proliferation. *Cell Prolif.* 2014 Apr;47(2):133-45.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA